Trial reportRadiology. Imaging cancer2022
Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.
Open access · diamondAbstract readClinical Trial
In one paragraph
Trial report in Radiology. Imaging cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers.Journal of neuroendocrinology · 2025Review
- Imaging DNA damage response by γH2AXTheranostics · 2023Article
- Intra-individual qualitative and quantitative comparison of [Therapeutic advances in medical oncology · 2023Article
- Head-to-Head Comparison between Peptide-Based Radiopharmaceutical for PET and SPECT in the Evaluation of Neuroendocrine Tumors: A Systematic Review.Current issues in molecular biology · 2022Review
- Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Vincent VandecaveyeFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).ORCID 0000-0002-0800-3279
Raphaëla C DresenFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Elin PauwelsFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Sofie Van BinnebeekFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Ragna VanslembrouckFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Kristof BaeteFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Felix M MottaghyFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Paul M ClementFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Kristiaan NackaertsFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Eric Van CutsemFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Chris VerslypeFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Frederik De KeyzerFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
Christophe M DerooseFrom the Departments of Radiology (V.V., R.C.D., R.V., F.D.K.), Nuclear Medicine (E.P., K.B., C.M.D.), Medical Oncology (P.M.C.), Pulmonology/Respiratory Oncology (K.N.), and Digestive Oncology (E.V.C., C.V.), University Hospitals Leuven, Herestraat 49, Leuven, Belgium; Department of Translational MRI, Imaging and Pathology (V.V., R.C.D.), Department of Nuclear Medicine and Molecular Imaging, Imaging and Pathology (E.P., C.M.D.), and Department of Oncology (P.M.C.), KU Leuven, Leuven, Belgium; Department of Nuclear Medicine, AZ Jan Portaels, Vilvoorde, Belgium (S.V.B.); Department of Nuclear Medicine, Imelda Ziekenhuis, Bonheiden, Belgium (S.V.B.); Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany (F.M.M.); and Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (F.M.M.).
KU Leuven · BE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To evaluate the predictive value of 7-week apparent diffusion coefficient change from baseline (ADCratio
Indexed as
Neuroendocrine TumorsAgedFemaleGallium RadioisotopesHumansKi-67 AntigenMaleMiddle AgedPositron Emission Tomography Computed TomographyProspective StudiesReceptors, PeptideGallium RadioisotopesKi-67 AntigenReceptors, PeptideMetastasesMR–Diffusion-Weighted ImagingRadionuclide TherapyTreatment EffectsTumor ResponseWhole-Body Imaging
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.